VCYT (Veracyte) Shiller PE Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCYT Veracyte Inc VCYT
79 GF Score
Price $41.46
GF Value $38.76
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Veracyte Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Veracyte  (NAS:VCYT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Veracyte Shiller PE Ratio Related Terms


Veracyte Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Veracyte's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte Shiller PE Ratio Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Veracyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

VCYT vs RDNT, SHC, ADPT: Shiller PE Ratio Comparison

For the Diagnostics & Research subindustry, Veracyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Shiller PE Ratio falls into.


VCYT
79GF Score
Veracyte Inc VCYT
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Veracyte's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Veracyte's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.31/333.9520*333.9520
=0.310

Current CPI (Jun. 2026) = 333.9520.

Veracyte Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.200 241.428 -0.277
201612 -0.140 241.432 -0.194
201703 -0.240 243.801 -0.329
201706 -0.220 244.955 -0.300
201709 -0.210 246.819 -0.284
201712 -0.240 246.524 -0.325
201803 -0.270 249.554 -0.361
201806 -0.180 251.989 -0.239
201809 -0.120 252.439 -0.159
201812 -0.080 251.233 -0.106
201903 -0.050 254.202 -0.066
201906 -0.050 256.143 -0.065
201909 -0.020 256.759 -0.026
201912 -0.150 256.974 -0.195
202003 -0.240 258.115 -0.311
202006 -0.220 257.797 -0.285
202009 -0.080 260.280 -0.103
202012 -0.140 260.474 -0.179
202103 -0.660 264.877 -0.832
202106 -0.130 271.696 -0.160
202109 -0.200 274.310 -0.243
202112 -0.150 278.802 -0.180
202203 -0.200 287.504 -0.232
202206 -0.130 296.311 -0.147
202209 -0.120 296.808 -0.135
202212 -0.050 296.797 -0.056
202303 -0.110 301.836 -0.122
202306 -0.120 305.109 -0.131
202309 -0.410 307.789 -0.445
202312 -0.390 306.746 -0.425
202403 -0.020 312.332 -0.021
202406 0.070 314.175 0.074
202409 0.190 315.301 0.201
202412 0.060 315.605 0.063
202503 0.090 319.799 0.094
202506 -0.010 322.561 -0.010
202509 0.240 324.800 0.247
202512 0.510 324.054 0.526
202603 0.350 330.213 0.354
202606 0.310 333.952 0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $41.46 is trading 7% above its estimated GF Value™ of $38.76. GuruFocus considers Veracyte to be Fairly Valued.

Key valuation signals for VCYT:

  • Shiller PE Ratio:
  • GF Value™: $38.76 vs. price of $41.46 (7% above fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
79GF Score

Get the complete analysis for VCYT

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.46
Price
$38.76
GF Value